SG11201509855VA - Method for preventing and/or treating chronic traumatic encephalopathy-ii - Google Patents

Method for preventing and/or treating chronic traumatic encephalopathy-ii

Info

Publication number
SG11201509855VA
SG11201509855VA SG11201509855VA SG11201509855VA SG11201509855VA SG 11201509855V A SG11201509855V A SG 11201509855VA SG 11201509855V A SG11201509855V A SG 11201509855VA SG 11201509855V A SG11201509855V A SG 11201509855VA SG 11201509855V A SG11201509855V A SG 11201509855VA
Authority
SG
Singapore
Prior art keywords
preventing
treating chronic
chronic traumatic
traumatic encephalopathy
encephalopathy
Prior art date
Application number
SG11201509855VA
Other languages
English (en)
Inventor
Robert Vink
Original Assignee
Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013902457A external-priority patent/AU2013902457A0/en
Application filed by Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro filed Critical Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro
Publication of SG11201509855VA publication Critical patent/SG11201509855VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Pyridine Compounds (AREA)
SG11201509855VA 2013-07-02 2014-07-02 Method for preventing and/or treating chronic traumatic encephalopathy-ii SG11201509855VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013902457A AU2013902457A0 (en) 2013-07-02 Method for preventing and/or treating chronic traumatic encephalopathy - ii
PCT/AU2014/050108 WO2015000033A1 (fr) 2013-07-02 2014-07-02 Procédé pour la prévention et/ou le traitement de l'encéphalopathie traumatique chronique-ii

Publications (1)

Publication Number Publication Date
SG11201509855VA true SG11201509855VA (en) 2016-01-28

Family

ID=52142942

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509855VA SG11201509855VA (en) 2013-07-02 2014-07-02 Method for preventing and/or treating chronic traumatic encephalopathy-ii

Country Status (16)

Country Link
US (1) US20160136160A1 (fr)
EP (1) EP3016657B1 (fr)
JP (1) JP6464421B2 (fr)
KR (1) KR101903713B1 (fr)
CN (1) CN105358153A (fr)
AU (2) AU2014286926A1 (fr)
BR (1) BR112015032534B1 (fr)
CA (1) CA2914523A1 (fr)
HK (2) HK1220639A1 (fr)
IL (1) IL242898B (fr)
MX (1) MX2015017881A (fr)
NZ (1) NZ714708A (fr)
RU (1) RU2674653C2 (fr)
SG (1) SG11201509855VA (fr)
WO (1) WO2015000033A1 (fr)
ZA (1) ZA201508872B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746077A4 (fr) * 2018-02-02 2021-10-27 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Formulations parentérales et leurs utilisations
CA3089656A1 (fr) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Formulations orales et utilisations de celles-ci
AU2020337177A1 (en) * 2019-08-23 2022-04-07 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury

Also Published As

Publication number Publication date
JP6464421B2 (ja) 2019-02-06
HK1220639A1 (zh) 2017-05-12
BR112015032534B1 (pt) 2020-03-03
BR112015032534A2 (pt) 2017-07-25
IL242898B (en) 2020-06-30
EP3016657B1 (fr) 2019-06-26
WO2015000033A1 (fr) 2015-01-08
CN105358153A (zh) 2016-02-24
NZ714708A (en) 2019-06-28
CA2914523A1 (fr) 2015-01-08
RU2016103098A (ru) 2017-08-03
RU2016103098A3 (fr) 2018-06-19
KR101903713B1 (ko) 2018-10-04
AU2019257499A1 (en) 2019-11-21
KR20160029066A (ko) 2016-03-14
US20160136160A1 (en) 2016-05-19
AU2014286926A1 (en) 2015-12-17
JP2016523262A (ja) 2016-08-08
MX2015017881A (es) 2016-09-14
EP3016657A1 (fr) 2016-05-11
EP3016657A4 (fr) 2017-03-22
RU2674653C2 (ru) 2018-12-12
ZA201508872B (en) 2017-08-30
HK1221637A1 (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
HK1221053A1 (zh) 用於保持或改善健康的方法和系統
IL245281A0 (en) Methods and preparations for the treatment of cancer
PT3036247T (pt) Método e sistema para tratar lenhina
SG11201602220TA (en) Substrate treatment method and substrate treatment device
EP2954376A4 (fr) Procédés et systèmes de traitement de fluide
TWI563558B (en) Substrate treatment apparatus and substrate treatment method
EP2950884A4 (fr) Compositions et procédés pour traiter des plaies superficielles
IL243928A0 (en) Preparations and methods for the treatment of complementary related conditions
GB201420103D0 (en) Treating particles
EP2943442A4 (fr) Systèmes et procédés de traitement d'eaux usées
IL244118A0 (en) Compounds and methods for the treatment of chronic urticaria
HK1199204A1 (en) Composition for preventing or treating hangover
HK1219884A1 (zh) 用於治療白血病的方法和組合物
EP2948138A4 (fr) Méthode et composition pour le traitement de l'hypertonie spastique
HK1221637A1 (zh) 用於預防和/或治療 型慢性創傷性腦病的方法
IL240619B (en) Method and system for water treatment
EP2981339A4 (fr) Systèmes et procédés de paris avancés
HK1220642A1 (zh) 用於預防和/或治療 型慢性創傷性腦病的方法
EP3065889A4 (fr) Composition et procédé de traitement de systèmes d'eau
GB201603140D0 (en) Method and apparatus for back-flow prevention
EP2969149A4 (fr) Procédé et dispositif pour traiter le cancer
EP3016659A4 (fr) Procédé de prévention et/ou traitement de l'encéphalopathie traumatique chronique-iii
IL246185A0 (en) Methods and compositions for treating dysregulation in systems
GB201311984D0 (en) Methods and compounds for preventing or treating osteoarthritis
EP2971044A4 (fr) Compositions et méthodes pour le traitement du cancer